is metformin like semaglutide Metabolic and safety outcomes with vs placebo by baseline Metformin vs. Semaglutide: A detailed

It should be the beginning of a permanent changenot a temporary exception to the longstanding rule

Last weeks JAMA had two articles on GLP-1 drugs that point to their promise for treatment of diseases beyond the conditions for which they are already approved by the FDA: obesity, diabetes, cardiovascular risk, sleep apnea and metabolic liver disease

Dolgintsev, Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats, Bull

Research on glycocalyx protectants (such as phillyrin and sphingosine-1-phosphate) is still in its early stages and relies on animal models and in vitro experiments [76, 121]

Rights and permissions About this article Cite this article Chiechio, S., Copani, A., Gereau, R.W